StockNews.com Lowers Actinium Pharmaceuticals (NYSE:ATNM) to Sell

StockNews.com downgraded shares of Actinium Pharmaceuticals (NYSE:ATNM) from a hold rating to a sell rating in a research note issued to investors on Wednesday morning.

Several other equities analysts have also recently issued reports on the company. B. Riley cut Actinium Pharmaceuticals from a buy rating to a neutral rating and dropped their price target for the company from $16.00 to $2.00 in a research report on Wednesday, August 7th. HC Wainwright lowered their price objective on Actinium Pharmaceuticals from $50.00 to $4.00 and set a buy rating on the stock in a report on Tuesday, August 6th. Finally, Maxim Group lowered their price objective on Actinium Pharmaceuticals from $30.00 to $5.00 and set a buy rating on the stock in a report on Tuesday, August 6th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of Moderate Buy and an average target price of $11.40.

Actinium Pharmaceuticals Price Performance

Shares of ATNM stock opened at $1.80 on Wednesday. The firm has a market cap of $53.61 million, a PE ratio of -1.05 and a beta of 0.14. Actinium Pharmaceuticals has a 52-week low of $1.33 and a 52-week high of $10.24. The firm has a 50-day moving average of $3.69.

Actinium Pharmaceuticals (NYSE:ATNM) last issued its quarterly earnings results on Monday, August 5th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.02. As a group, equities research analysts predict that Actinium Pharmaceuticals will post -1.38 earnings per share for the current year.

Institutional Investors Weigh In On Actinium Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of ATNM. Sanders Morris Harris LLC purchased a new stake in Actinium Pharmaceuticals in the 1st quarter valued at approximately $78,000. Vanguard Group Inc. lifted its stake in Actinium Pharmaceuticals by 6.0% in the 1st quarter. Vanguard Group Inc. now owns 1,446,326 shares of the company’s stock valued at $11,325,000 after buying an additional 82,113 shares in the last quarter. Virtu Financial LLC lifted its stake in Actinium Pharmaceuticals by 319.2% in the 1st quarter. Virtu Financial LLC now owns 82,029 shares of the company’s stock valued at $642,000 after buying an additional 62,459 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in Actinium Pharmaceuticals by 28.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 86,401 shares of the company’s stock valued at $639,000 after buying an additional 19,035 shares in the last quarter. Finally, Rhumbline Advisers lifted its stake in Actinium Pharmaceuticals by 23.4% in the 2nd quarter. Rhumbline Advisers now owns 39,656 shares of the company’s stock valued at $293,000 after buying an additional 7,525 shares in the last quarter. Hedge funds and other institutional investors own 27.50% of the company’s stock.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.